Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

135 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-20

Study Completion Date

2018-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is aimed at assessing IGF-1R-Abs in patients with Graves' disease, with or without GO, compared with healthy subjects and patients with autoimmune thyroiditis in a cross-sectional investigation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T and B Cells in Graves' Orbitopathy

NCT03195296

Graves Ophthalmopathy

COMPLETED

Low-dose Radioiodine Ablation in Graves' Disease

NCT03110835

Thyroid Diseases

COMPLETED

Rituximab in the Treatment of Graves' Disease

NCT00150111

Graves´ Disease Thyroid Associated Ophthalmopathy

COMPLETED PHASE1/PHASE2

Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

NCT00430547

Graves' Ophthalmopathy

COMPLETED NA

Immunological Follow-up of Patients With Basedow's Orbitopathy

NCT04610723

Graves Orbitopathy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graves Ophthalmopathy Graves Disease Autoimmune Thyroiditis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Graves' diseases

Patients with Graves' disease. No interventions foreseen

Serum antibodies against the IGF-1R

Intervention Type DIAGNOSTIC_TEST

Measurement of antibodies against the IGF-1R in serum samples by ELISA

Autoimmune thyroiditis

Patients with autoimmune thyroiditis. No interventions foreseen

Serum antibodies against the IGF-1R

Intervention Type DIAGNOSTIC_TEST

Measurement of antibodies against the IGF-1R in serum samples by ELISA

Healthy Subjects

Normal healthy subjects. No interventions foreseen

Serum antibodies against the IGF-1R

Intervention Type DIAGNOSTIC_TEST

Measurement of antibodies against the IGF-1R in serum samples by ELISA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum antibodies against the IGF-1R

Measurement of antibodies against the IGF-1R in serum samples by ELISA

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. for Graves' disease: a history of hyperthyroidism, associated with previous or present detectable serum autoantibodies against the TSH-R;
2. for autoimmune thyroiditis: the presence of at least two of the following: a) primary hypothyroidism; b) detectable serum autoantibodies against thyroglobulin or thyroperoxidase ; c) a hypoechoic pattern of the thyroid by ultrasound examination.
3. for healthy subjects: absence of any clinical, biochemical or instrumental evidence of thyroid diseases.

For all subjects: Informed consent